NAD research is active, but a headline about the field is not necessarily evidence for the product being advertised. This reading guide was checked September 18, 2026; it is a selected evidence map, not a continuously updated news feed or a systematic review.
Start every paper with three questions: what was administered, to whom, and what actually changed? Those details keep a finding about oral NR from becoming an unsupported promise about an NAD infusion.
NAD research is active, but a headline about the field is not necessarily evidence for the product being advertised. This reading guide was checked September 18, 2026; it is a selected evidence map, not a continuously updated news feed or a systematic review.
Oral NR: biomarker findings
The 2018 randomized crossover study in middle-aged and older adults supports a short-term finding about NAD-related measurements and tolerability. Its design does not establish extended lifespan. When a retailer cites it, compare the ingredient and preparation with the product's label. A related pathway is not an exact-product match.
NMN: a specific metabolic population
The 2021 randomized study of postmenopausal women with prediabetes reported a muscle insulin-sensitivity effect. That result deserves its actual context rather than a generic “burns fat” headline. Our weight-loss article explains why metabolic endpoints should not be rewritten as proven weight reduction from NAD shots.
Whole-blood NAD and age: a 2026 update
The 2026 human whole-blood study found no age-related decline in its data, challenging a common blanket marketing premise. Different tissues, methods, and populations may yield different observations. The testing guide places the result beside earlier human findings without turning either into a personal age chart.
Brain trials and IV tolerability
The 2026 NR cognitive pilot and retrospective IV tolerability research answer different questions. A tolerability comparison is not an efficacy trial; a blood biomarker rise is not necessarily better cognition. Read brain and memory evidence and IV therapy for the route-specific implications.
Worked examples include the long-COVID placebo comparison, phase I Parkinson’s research, and the exercise trial’s prespecified statistical threshold. Each illustrates a different limit on a headline claim.
A checklist for the next headline
Find the original paper and publication date. Identify cells, animals, or humans; sample size; comparator; route; duration; prespecified outcomes; adverse events; and funding. Check whether a result was statistically and clinically meaningful, and whether negative outcomes were omitted from the headline. A trial registration describes a planned study, not a positive result. Keep the full evidence boundary when sharing the claim.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Martens et al. (2018): randomized oral NR crossover trial Short-term human biomarker and tolerability study; not a lifespan trial.
- Yoshino et al. (2021): NMN and muscle insulin sensitivity Small randomized study in postmenopausal women with prediabetes; not evidence for NAD injections or general weight loss.
- Trętowicz et al. (2026): whole-blood NAD and age Human study reporting no age-related whole-blood decline; does not measure every tissue.
- Phase II NR pilot in amnestic mild cognitive impairment (2026) Pilot trial; NAD biomarker increases did not establish improved principal cognitive outcomes.
- Reyna et al. (2026): retrospective IV tolerability pilot Route-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.